FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:65-67 January 2, 1997 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Related Article by The Multicenter Acute Stroke Trial — Europe Study Group PubMed Citation

To the Editor: The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group would like to respond to comments by the Multicenter Acute Stroke Trial — Europe (MAST-E) investigators (July 18 issue),¹ who claimed that the positive results of the NINDS trial could be "due to chance."

Our study group reported the results of two separate but identically designed, double-blind trials with different primary and secondary end points.² Part 2 was designed to confirm the findings of Part 1. The benefit found for tissue plasminogen activator (t-PA) at three months was seen in both parts of the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kwiatkowski, T. G., Libman, R. B., Frankel, M., Tilley, B. C., Morgenstern, L. B., Lu, M., Broderick, J. P., Lewandowski, C. A., Marler, J. R., Levine, S. R., Brott, T., The National Institute of Neurological Disorders a, (1999). Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year. NEJM 340: 1781-1787 [Abstract] [Full Text]